OC
FOLD

Oppenheimer & Co’s Amicus Therapeutics FOLD Stock Holding History

Oppenheimer & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-23,409
Closed -$167K – 1316
2017
Q1 		$167K Sell
23,409
-17,584
-43% -$111K ﹤0.01% 1200
2016
Q4 		$204K Buy
+40,993
New +$284K 0.01% 1156

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Oppenheimer & Co's FOLD Position: Q2 2017 in Review

Oppenheimer & Co sold out of Amicus Therapeutics (FOLD) in Q2 2017, closing a stake of 23,409 shares — an estimated $167K sold.

Oppenheimer & Co first reported a position in FOLD in Q4 2016 and held it in 2 quarters. The position peaked at $204K in Q4 2016. 141 funds tracked by Wall St. Rank hold FOLD as of Q2 2017.

  • Oppenheimer & Co reported no remaining Amicus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Oppenheimer & Co sold 23,409 Amicus Therapeutics shares in Q2 2017, an estimated $167K.
  • Oppenheimer & Co first reported a position in Amicus Therapeutics in Q4 2016 and held it in 2 quarters.
  • Oppenheimer & Co's Amicus Therapeutics position peaked at $204K in Q4 2016.
  • 141 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2017.

Based on Oppenheimer & Co's 13F filing for Q2 2017, filed 9 Aug 2017.